J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
Times Cited: 221
Times Cited: 221
R A Pederson, J C Brown. Endocrinology 1978
Times Cited: 123
Times Cited: 123
List of shared articles
Times cited
Glucagon's Metabolic Action in Health and Disease.
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, Shelly Nason, Kirk M Habegger, Timo D Müller. Compr Physiol 2021
Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, Shelly Nason, Kirk M Habegger, Timo D Müller. Compr Physiol 2021
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer. Diabetes Obes Metab 2021
Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer. Diabetes Obes Metab 2021
Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
Gerald Grandl, Aaron Novikoff, Richard DiMarchi, Matthias H Tschöp, Timo D Müller. Compr Physiol 2019
Gerald Grandl, Aaron Novikoff, Richard DiMarchi, Matthias H Tschöp, Timo D Müller. Compr Physiol 2019
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists.
T D Müller, C Clemmensen, B Finan, R D DiMarchi, M H Tschöp. Pharmacol Rev 2018
T D Müller, C Clemmensen, B Finan, R D DiMarchi, M H Tschöp. Pharmacol Rev 2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
The New Biology and Pharmacology of Glucagon.
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes.
Dan Kawamori. Diabetol Int 2017
Dan Kawamori. Diabetol Int 2017
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. J Diabetes Res 2015
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. J Diabetes Res 2015
Glucagon and type 2 diabetes: the return of the alpha cell.
Asger Lund, Jonatan I Bagger, Mikkel Christensen, Filip K Knop, Tina Vilsbøll. Curr Diab Rep 2014
Asger Lund, Jonatan I Bagger, Mikkel Christensen, Filip K Knop, Tina Vilsbøll. Curr Diab Rep 2014